[Anthracycline transport in sensitive and resistant leukemia cells]
Standard
[Anthracycline transport in sensitive and resistant leukemia cells]. / Erttmann, Rudolf; Erb, Norbert; Forcadell de Dios, P; Neurath, C; Looft, G; Landbeck, G.
in: KLIN PADIATR, Jahrgang 201, Nr. 1, 1, 1989, S. 40-45.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Anthracycline transport in sensitive and resistant leukemia cells]
AU - Erttmann, Rudolf
AU - Erb, Norbert
AU - Forcadell de Dios, P
AU - Neurath, C
AU - Looft, G
AU - Landbeck, G
PY - 1989
Y1 - 1989
N2 - The in-vitro uptake of four anthracyclines into leukemic cells was investigated. The accumulation was found to be dependent on the extracellular anthracycline concentration in a linear fashion. The steady state intracellular drug level was reached very quickly and was found to be correlated to the extracellular pH-value in the range between 6.4 and 7.4. Intracellular anthracycline accumulation was restricted in a leukemic subline (F 4-6 R), which was found to be 86 times more resistant to doxorubicin compared with its wild tpye (F 4-6). The importance of the initial uptake phase of anthracyclines into leukemic cells raises the question whether long-term "cardioprotective" anthracycline application schedules will retain the same antileukemic effect as conventional bolus injection.
AB - The in-vitro uptake of four anthracyclines into leukemic cells was investigated. The accumulation was found to be dependent on the extracellular anthracycline concentration in a linear fashion. The steady state intracellular drug level was reached very quickly and was found to be correlated to the extracellular pH-value in the range between 6.4 and 7.4. Intracellular anthracycline accumulation was restricted in a leukemic subline (F 4-6 R), which was found to be 86 times more resistant to doxorubicin compared with its wild tpye (F 4-6). The importance of the initial uptake phase of anthracyclines into leukemic cells raises the question whether long-term "cardioprotective" anthracycline application schedules will retain the same antileukemic effect as conventional bolus injection.
M3 - SCORING: Zeitschriftenaufsatz
VL - 201
SP - 40
EP - 45
JO - KLIN PADIATR
JF - KLIN PADIATR
SN - 0300-8630
IS - 1
M1 - 1
ER -